Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 241 results
Press release cover image

Oct 21, 2026

bitBiome Achieves Milestones in Joint Development Project with Ajinomoto Co., Inc.

TOKYO, Oct. 20, 2026 /PRNewswire/ -- bitBiome, Inc. (Headquarters: Tokyo; Representative Director and CEO: Yuji Suzuki) is pleased to announce the achievement of target milestones stipulated in the joint development contract with Ajinomoto Co., Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Shigeo Nakamura), which was previously announced on December 21, 2023. In recognition of this milestone, bitBiome has received the associated success fee.In this project, bitBiome utilized its propr
Press release cover image

Oct 21, 2026

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpretation to generate clearer mechanistic hypothesesMORRISVILLE, N.C., Oct. 20, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics solutions advancing life sciences research, diagnostics, therapeutics, and precision medicine, today announced Splash & Ripple, a new bioinformatics application within the company's Integrate
Press release cover image

Oct 20, 2026

Myllia Biotechnology Appoints Board with Industry Leaders

Single-cell commercial leader Simone Günther, US biotechveteran Sandy Zweifach, and Werner Lanthaler (Wlanholding) join to guideMyllia's next phase of growthVienna, Austria – October 8, 2026 – MylliaBiotechnology, a specialist in high-content CRISPR screens in primary humancells, today announced the formation of its Board. The new governance body willoversee and advise Myllia's management team, led by co-founders Dr. ThomasMoser (CEO) and Dr. Tilmann Buerckstuemmer (CSO). The Board comprises San
Press release cover image

Oct 20, 2026

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratificationPresentations reflect Guardant’s strong biopharma and academic collaborations, along with public-private partnerships in EuropePALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—includin
Press release cover image

Oct 20, 2026

BostonGene and Medical University of South Carolina Announce Strategic Collaboration to Advance CAR-T Therapy Insights for Lymphoma and Leukemia

Collaboration leverages biologically grounded AI and multimodal immune system profiling via RNA sequencing and flow cytometry to identify predictive biomarkers of CAR-T response, toxicity, persistence, and immune dynamicsWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced a new research collaboration with the Medical University of South Carolina (MUSC). The collaboration will leverage BostonGene’s biologically grounded AI p
Press release cover image

Oct 20, 2026

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers soonerGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS).Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain stru
Press release cover image

Oct 20, 2026

Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility

New modular platform gives researchers greater control over sample and cell throughput while optimizing valueSEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up
Press release cover image

Oct 20, 2026

Sinopia Biosciences Secures $2.5 Million NIH Grant to Advance Metabolomics Foundation Model for Drug Discovery

NIGMS SBIR Phase II award will support development of an AI-powered metabolomics foundation model designed to unify insights across metabolomics data and accelerate therapeutic discovery through Sinopia's LEADS® platformSAN DIEGO--(BUSINESS WIRE)--Sinopia Biosciences, Inc., a biotechnology company leveraging multi-omics data, high-throughput screening, and artificial intelligence to identify and develop first-in-class therapies for diseases with significant unmet need, today announced it has bee
A permafrost core sample on the Arctic tundra

Oct 20, 2026

Canada’s Arctic Research Could Help Discover Next-Gen Therapeutics

Exploration of Canada’s Arctic permafrost may unveil new therapeutic compounds, but ethical considerations loom large.Canadian scientists are investigating the Arctic tundra's permafrost, which holds ancient DNA and potentially valuable microorganisms for drug development. Utilizing advanced genomic techniques, researchers aim to uncover biosynthetic gene clusters that could lead to innovative antibiotics and other therapeutics. The historical significance of these organisms, some preserved for
Illustration of RNA fusion

Oct 20, 2026

New Pipeline Reveals RNA Fusions Formed During Inflammation, Opens New Frontier in Biology

Recent research has unveiled a groundbreaking mechanism by which immune cells generate novel messenger RNAs during inflammatory responses, potentially redefining our understanding of gene functionality.Scientists have discovered that during inflammation, immune cells can create chimeric mRNAs by fusing segments from disparate genes, a process previously thought to result mainly from DNA damage. This study, led by researchers at Harvard Medical School, demonstrates that these fused RNAs play a si
Press release cover image

Oct 20, 2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyondGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis an
Press release cover image

Oct 20, 2026

Baylor Genetics to Highlight Clinical and Diagnostic Utility of Genome Sequencing at the 2026 American Society of Human Genetics Annual Meeting

HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it will share new genome sequencing data in two platform presentations and a poster presentation at the 2026 American Society of Human Genetics (ASHG) Annual Meeting in Montréal, Québec, Canada from Oct. 20-24, 2026. “The data we’re sharing at this year’s ASHG meeting reinforces the role of genome seque